Impact of the use of epoetin beta on sustained virological response in patients with hepatitis C virus treated with pegylated interferon alfa-2a plus ribavirin

Trial Profile

Impact of the use of epoetin beta on sustained virological response in patients with hepatitis C virus treated with pegylated interferon alfa-2a plus ribavirin

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2011

At a glance

  • Drugs Epoetin beta (Primary) ; Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms PEGEPO
  • Most Recent Events

    • 08 Nov 2011 Results presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases.
    • 20 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top